Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential
A Phase 1, Open-Label Study to Evaluate the Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Daytona Beach, Florida, United States, 32117
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female subjects between 18 and 65 years of age, inclusive.
- Female subjects of non-childbearing potential including non-pregnant, non-lactating, and either postmenopausal or surgically sterile for at least 45 days post procedure.
- Within BMI range 18.5 to </= 29.9 kg/m^2, inclusive.
- In good health, as determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory evaluations.
- Receive an explanation of the mandatory pharmacogenomic (PgX) component of the study.
Exclusion Criteria:
- Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder.
- Previous history of adverse reaction to statins.
- Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days or 5 half-lives, whichever is longer, prior to Check-in (Day -1) in Period 1.
- Use of systemic hormone replacement therapy within 1 year prior to Check-in (Day -1).
- History of use of tamoxifen, aromatase inhibitor or any other endocrine agent for treatment of breast cancer.
- Female subject is pregnant lactating, or breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Female Healthy Volunteers
Healthy volunteer female subjects of non-childbearing potential will be administered pravastatin once on Day 1 during Period 1 (Day -1 to Day 4).
During Period 2 (Days 5-28) GDC-0810 will be administered daily on Days 5-8.
Pravastatin will be co-administered on Day 7.
|
During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
Other Names:
Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Observed Concentration (Cmax) of Pravastatin
Time Frame: Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
|
Time to Maximum Concentration (Tmax) of Pravastatin
Time Frame: Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
|
Area Under the Concentration-Time Curve from Hour 0 to the Last Measurable Concentration (AUC0-t) of Pravastatin
Time Frame: Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
|
Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of Pravastatin
Time Frame: Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
|
Apparent Volume of Distribution (Vz/F) of Pravastatin
Time Frame: Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
|
Apparent Clearance (CL/F) of Pravastatin
Time Frame: Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
|
Apparent Terminal Elimination Rate Constant (lambda z) of Pravastatin
Time Frame: Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
|
Apparent Terminal Elimination Half-Life (t1/2) of Pravastatin
Time Frame: Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
|
Amount of Pravastatin Excreted in Urine (Ae)
Time Frame: Day 1 (Period 1) and Day 7 (Period 2)
|
Day 1 (Period 1) and Day 7 (Period 2)
|
|
Renal Clearance (CLR) of Pravastatin
Time Frame: Day 1 (Period 1) and Day 7 (Period 2)
|
Day 1 (Period 1) and Day 7 (Period 2)
|
|
Percentage of Pravastatin Excreted in Urine (%Excreted)
Time Frame: Day 1 (Period 1) and Day 7 (Period 2)
|
Day 1 (Period 1) and Day 7 (Period 2)
|
|
Plasma Concentrations of Pravastatin
Time Frame: Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Days 1-3 (Period 1) and Days 7-10 (Period 2)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Observed Concentration (Cmax) of GDC-0810
Time Frame: Days 7-10 (Period 2)
|
Days 7-10 (Period 2)
|
|
Time to Maximum Concentration (Tmax) of GDC-0810
Time Frame: Days 7-10 (Period 2)
|
Days 7-10 (Period 2)
|
|
Area Under the Concentration-Time Curve from Hour 0 to the Last Measurable Concentration (AUC0-t) of GDC-0810
Time Frame: Days 7-10 (Period 2)
|
Days 7-10 (Period 2)
|
|
Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of GDC-0810
Time Frame: Days 7-10 (Period 2)
|
Days 7-10 (Period 2)
|
|
Apparent Volume of Distribution (Vz/F) of GDC-0810
Time Frame: Days 7-10 (Period 2)
|
Days 7-10 (Period 2)
|
|
Apparent Clearance (CL/F) of GDC-0810
Time Frame: Days 7-10 (Period 2)
|
Days 7-10 (Period 2)
|
|
Apparent Terminal Elimination Rate Constant (lambda z) of GDC-0810
Time Frame: Days 7-10 (Period 2)
|
Days 7-10 (Period 2)
|
|
Apparent Terminal Elimination Half-Life (t1/2) of GDC-0810
Time Frame: Days 7-10 (Period 2)
|
Days 7-10 (Period 2)
|
|
Amount of GDC-0810 Excreted in Urine (Ae)
Time Frame: Day 7 (Period 2)
|
Day 7 (Period 2)
|
|
Renal Clearance (CLr) of GDC-0810
Time Frame: Day 7 (Period 2)
|
Day 7 (Period 2)
|
|
Percentage of GDC-0810 Excreted in Urine (%Excreted)
Time Frame: Day 7 (Period 2)
|
Day 7 (Period 2)
|
|
Percentage of Participants with Adverse Events (AEs)
Time Frame: From baseline to study completion up to Day 28
|
From baseline to study completion up to Day 28
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
Time Frame: From baseline to study completion up to Day 28
|
From baseline to study completion up to Day 28
|
|
Percentage of Participants with Clinically Significant Changes in Safety Measurements, Including Vital Signs, Electrocardiograms (ECGs), Physical Examination Findings and Clinical Laboratory Results.
Time Frame: From baseline to study completion up to Day 28
|
From baseline to study completion up to Day 28
|
|
Plasma Concentrations of GDC-0810
Time Frame: Days 7-10 (Period 2)
|
Days 7-10 (Period 2)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GP29825
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.